Predictive Oncology enters ATM sales agreement for up to $3.7M of common stock with H.C. Wainwright

Axe Compute Inc.

Entered ATM Sales Agreement with H.C. Wainwright for up to $3,696,000 of common stock.
Shares sold through 'at the market offering'; 3.0% commission to agent.
No obligation to sell; Company may set parameters including minimum price.
Registration statement on Form S-3 to be filed; sales subject to effectiveness.
Stock trades on NASDAQ Capital Market under symbol POAI.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Axe Compute Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at $3,696,000 (effective 2024-05-03).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: $3,696,000
Effective: 2024-05-03

Exact text from the filing

On May 3, 2024, Predictive Oncology Inc., a Delaware corporation, (the “Company”), entered into an ATM Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock, par value $0.01 per share, from time to time, through an “at the market offering” program pursuant to which Wainwright will act as sales agent.

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002541

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.